News Release

Cannabidiol for scan-related anxiety in women with advanced breast cancer

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: The findings of this randomized clinical trial show that cannabidiol (CBD) can be used safely in women with advanced breast cancer and clinical anxiety. Although the study did not meet its primary end point comparing pre-ingestion vs post-ingestion anxiety change scores between study arms, anxiety levels in the CBD arm were significantly lower 2 to 4 hours after ingestion, suggesting a possible anxiolytic effect and warranting further investigation.

Corresponding Author: To contact the corresponding author, Ilana M. Braun, MD, email ilana_braun@dfci.harvard.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2024.50391)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.50391?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=121624

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.